216 313

Cited 6 times in

PET imaging of HER2 expression with an 18F-fluoride labeled aptamer

Authors
 Hyun Jeong Kim  ;  Jun Young Park  ;  Tae Sup Lee  ;  In Ho Song  ;  Ye Lim Cho  ;  Ju Ri Chae  ;  Hyungu Kang  ;  Jong Hoon Lim  ;  Jung Hwan Lee  ;  Won Jun Kang 
Citation
 PLOS ONE, Vol.14(1) : e0211047, 2019 
Journal Title
 PLOS ONE 
Issue Date
2019
Abstract
BACKGROUND/PURPOSE: Aptamers are oligonucleotide or peptide molecules that bind to a target molecule with high affinity and specificity. The present study aimed to evaluate the target specificity and applicability for in vivo molecular imaging of an aptamer labeled with a radioisotope. METHODS: The human epidermal growth factor receptor 2 (HER2/ErbB2) aptamer was radiolabeled with 18F-fluoride. HER2-positive tumor cell uptake of the aptamer was evaluated in comparison to negative controls by flow cytometry and confocal microscopy. Using 18F-labeled HER2-specific aptamer positron emission tomography (PET), in vivo molecular images of BT474 tumor-bearing mice were taken at 60, 90 and 120 minutes after injection. RESULTS: In flow cytometric analysis, HER2 aptamer showed strong binding to HER2-positive BT474 cells, while binding to HER2-negative MDA-MB231 cells was quite low. Likewise, in confocal microscopic images, the aptamer was bound to HER2-positive breast cancer cells, with minimal binding to HER2-negative cells. In vivo PET molecular imaging of BT474 tumor-bearing mice revealed significant higher uptake of the 18F-labeled HER2 specific aptamer into the tumor compared to the that of HER2-negative cell tumor(p = 0.033). HER2 aptamer was able to preferentially bind to HER2-positive breast cancer cells both in vitro and in vivo, by recognizing HER2 structure on the surface of these cells. CONCLUSION: The 18F-labeled aptamer enabled appropriate visualization of HER2 expression by human breast cancer cells. The results suggest that a radiolabeled HER2 aptamer could potentially be applied in the development of treatment strategies or in targeted therapy against HER2-positive breast cancer cells.
Files in This Item:
T201900862.pdf Download
DOI
10.1371/journal.pone.0211047
Appears in Collections:
6. Others (기타) > Gangnam Severance Hospital Health Promotion Center(강남세브란스병원 체크업) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers
Yonsei Authors
Kang, Won Jun(강원준) ORCID logo https://orcid.org/0000-0002-2107-8160
Kim, Hyun Jeong(김현정) ORCID logo https://orcid.org/0000-0002-3116-8848
Park, Jun Young(박준영) ORCID logo https://orcid.org/0000-0003-3403-2767
Cho, Ye Lim(조예림)
Chae, Ju Ri(채주리)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/169550
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links